CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 445 enrolled
Drug / intervention
Percutaneous Coronary Interventiondevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04192747
NCT04192747N/AActive
CompareCT.gov

Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De Novo Native Coronary Arteries ELX-CL-1805

Elixir Medical Corporation·interventional·Posted Dec 10, 2019·Updated Mar 24, 2025

In Brief

A clinical study evaluating Percutaneous Coronary Intervention for Coronary Artery Disease and 3 related conditions. Active but no longer recruiting, targeting 445 participants across 36 sites in 4 countries.

Detailed Summary

The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
CountriesBelgium, Germany, Japan, New Zealand
Collaborators--

Timeline

N/AActive
20202021202220232024202520262027
First PostedDec 10, 2019
Enrollment StartDec 16, 2020
Primary CompletionFeb 28, 2023
Study CompletionFeb 28, 2027
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.6 years ago

Interventions

Percutaneous Coronary Interventiondevice

Percutaneous coronary intervention of de novo native coronary artery lesions